Meta AnalysisID 465
Viaskin®花生贴片与口服免疫疗法治疗花生过敏：有效性与价值
CRD42019120476
In patients with peanut allergy, what is the comparative efficacy, safety, and effectiveness of Viaskin Peanut and AR101 versus usual care/best supportive care including measures of quality of life, anaphylaxis, angioede
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 465
- Evidence Id
- 9023
- Core Evidence Id
- 9023
- Source Meta Analysis Id
- 440
- Herb2 Meta Analysis Id
- HBMA000440
- Crd Id
- CRD42019120476
- Title
- Viaskin® peanut and oral immunotherapy for peanut allergy: effectiveness and value
- Review Question
- In patients with peanut allergy, what is the comparative efficacy, safety, and effectiveness of Viaskin Peanut and AR101 versus usual care/best supportive care including measures of quality of life, anaphylaxis, angioedema, wheezing, parental anxiety, urticaria, adverse events, and other key outcomes?
- Study Type Included
- Evidence will be collected from available randomized controlled trials, non-randomized clinical trials, and high-quality systematic reviews; comparative observational studies will also be included if available. We will not restrict studies according to study duration or study setting; however, we will limit our review to those that include the specified populations and capture the outcomes of interest. We will supplement our review of published studies with data from conference proceedings, regulatory documents, information submitted by manufacturers, and other grey literature when the evidence meets ICER standards (for more information, see http://icer-review.org/methodology/icersmethods/ icer-value-assessment-framework/grey-literature-policy/).
- Condition Being Studied
- Peanut Allergy
- Participant
- Inclusion: children between the ages of 4 and 17 with peanut allergy
- Animal
- Human Disease Modelled
- Intervention
- Viaskin peanut, AR-101, oral immunotherapy with other peanut products
- Comparator Control
- Placebo/usual care
- Main Outcome
- The primary outcomes of interest from clinical trials will include desensitization to peanut antigen, use of epinephrine, quality of life, hospitalization, anaphylaxis and angieodema. Measures of effect Evidence on intervention effectiveness will be derived from studies of at least one year’s duration and evidence on harms from studies of at least three month’s duration.
- Outcome Measure
- Additional Outcome
- • Systematic reactions. • Skin reactions. • Gastrointestinal reactions. • Serious adverse events. • Adverse events leading to treatment discontinuation. • Parental anxiety/ depression. • Bronchospasm / wheezing. • Urticaria. Measures of effect Evidence on intervention effectiveness will be derived from studies of at least one year’s duration and evidence on harms from studies of at least three month’s duration.
- Study Method
- Systematic review
- Keyword
- Humans; Peanut Hypersensitivity
- Contact
- Jeffrey Tice, M.D. [email protected]
- Organisational Affiliation
- Institute for Clinical and Economic Review
- Funding Source
- ICER’s core work is supported by grants from the Laura and John Arnold Foundation, California Healthcare Foundation, Commonwealth Grant, NE States Consortium Systems Organization and National Institute for Health Care Management (NIHCM) ICER’s annual policy summit is supported by dues from the organizations listed below: Aetna, America’s Health Insurance Plans (AHIP), Allergan, Alnylam, Anthem, Astra Zeneca, Biogen, Blue Shield of CA, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/Roche, GSK, Harvard Pilgrim, Health Care Service Corporation, Health Partners, J&J (Janssen), Kaiser Permanente, LEO, Mallinckrodt, Merck, Novartis, NPC, Premera, Primer Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare
- Other Selection Criteria
- Final Publication
- ICER Institute for Clinical and Economic ReviewOral Immunotherapy and Viaskin® Peanut for Peanut Allergy: Effectiveness and Value. Final Evidence Report July 10, 2019 Jeffrey A. Tice, MD, Serina Herron-Smith, BA, Emily Tsiao, PharmD, Rick Chapman, PhD, MS, Remziye Zaim, MSc, MS, Celia Segel, MPP, David Rind, MD, MSc, Steven D. Pearson, MD, MSc, Greg Guzauskas, MSPH, PhD, Ryan N. Hansen, PhD, PharmD. https://icer-review.org/wp-content/uploads/2018/12/ICER_PeanutAllergy_Final_Report_071019.pdf
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- United States of America
- Review Stage
- Review Completed published
- First Submission Date
- 2019-01-16
- Registration Date
- 2019-02-01
- Anticipated Start Date
- 2018-12-20
- Anticipated Completion Date
- 2019-07-03
- Title Cn
- Viaskin®花生贴片与口服免疫疗法治疗花生过敏：有效性与价值
- Title En
- Viaskin® peanut and oral immunotherapy for peanut allergy: effectiveness and value
- Bilingual Status
- complete